* T Cell Sciences Inc., of Needham, Mass., said its subsidiary, T CellDiagnostics Inc., received clearance to market the TRAx CD4 TestKit as a method for enumerating CD4 T cells.* Medco Research Inc., of Research Triangle Park, N.C., andFujisawa USA Inc., of Deerfield, Ill., said the FDA grantedmarketing clearance for Adenoscan (adenosine injection), as acoronary vasodilator for use with radioactive thallium imaging inpatients unable to exercise adequately.* Genta Inc., of San Diego, expanded its joint venture, Genta Jago,with Switzerland-based Jagotec AG to develop controlled-releaseoral formulations of 35 drugs already on the market. The expansiongives Genta Jago about 60 drugs under development with Jagotec'sGeomatrix drug delivery technology. In addition, Genta Jagoreturned to Genta rights to its Anticode products.* Gilead Sciences Inc., of Foster City, Calif., began Phase I/II studiesof its antiviral drug, Cidofovir topical gel, for genital herpes simplexvirus in patients with normal immune systems. Cidofovir previouslywas called GS 504.* Immucell Corp., of Portland, Maine, reacquired rights to its bovineimmunoglobulin product, CryptoGAM, from Univax Biologics Inc.,of Rockville, Md. The two companies were developing the drug toprevent cryptosporidiosis in HIV patients and Immucell expects tohave Phase I/II trial results by the end of the year. Univax ended itsfunding of clinical trials of CryptoGAM as part of its recent businessrestructuring. (See BioWorld Today, May 16, 1995, p. 1.)* International Murex Technologies Corp., of Atlanta, will be listedon the NASDAQ National Market System board as of June 1 underthe new symbol, MURX. The company has been listed on theAmerican and Toronto Stock Exchanges.* Neurex Corp., of Menlo Park, Calif., said the FDA approvedexpansion of the company's Phase I/II trials of the pain drug, SNX-111, to include a wider population of cancer patients and patientswith non-cancer pain. The new criteria also remove limitations onlife-expectancy, however, patients enrolled in the studies must haveexperienced no response to opiate therapy.* Protein Design Labs Inc., of Mountain View, Calif., said data froma Phase I trial of the company's Smart Anti-Tac antibody, Zenapax,for kidney transplants showed that only one of 12 patientsexperienced graft rejection within six months after treatment withZenapax. The patients also receive the standard anti-rejection therapyconsisting of cyclosporine A, prednisone and azathioprine. Zanapaxis being developed by Hoffmann-La Roche Inc., of Nutley, N.J., incollaboration with Protein Design Labs.* SangStat Medical Corp., of Menlo Park, Calif., received FDAmarketing approval for Cross-Stat, a monitoring device used toidentify organ donors. The product was developed under a 1993agreement with Nextran Inc., a partnership between BaxterHealthcare Corp., of Deerfield, Ill., and DNX Corp., of Raritan, N.J.

(c) 1997 American Health Consultants. All rights reserved.